MW 258.05 Da, Purity >99%. Potent NMDA receptor glycine site antagonist. Water soluble form available - see (ab120254).
131123-76-7
> 99%
Solid
258.05 Da
C10H5Cl2NO3
1779
Synthetic
AMPA 1, AMPA 2, AMPA 3, AMPA 4, AMPA-selective glutamate receptor 1, AMPA-selective glutamate receptor 2, AMPA-selective glutamate receptor 3, AMPA-selective glutamate receptor 4, AW490526, EB11, EIEE27, EPND, FESD, GLUH1, GLUK3, GLUR4C, GRIA1_HUMAN, GRIA2_HUMAN, GRIA3_HUMAN, GRIA4_HUMAN, GRIN 2A, GRIN 2B, GRIN3A, GRIN3B, GluA 4, GluA1, GluA2, GluA3, GluN1, GluN2A, GluN2C, GluN2D, GluR-1, GluR-2, GluR-3, GluR-4, GluR-A, GluR-B, GluR-C, GluR-D, GluR-K1, GluR-K2, GluR-K3, Glutamate Receptor Ionotropic N Methyl D Aspartate 2B, Glutamate Receptor Ionotropic N Methyl D Aspartate 2C, Glutamate Receptor Ionotropic N Methyl D Aspartate subunit 2B, Glutamate Receptor Ionotropic N methyl D aspartate 3A, Glutamate [NMDA] receptor subunit epsilon-1, Glutamate [NMDA] receptor subunit epsilon-2, Glutamate [NMDA] receptor subunit epsilon-3, Glutamate [NMDA] receptor subunit epsilon-4, Glutamate [NMDA] receptor subunit zeta-1, Glutamate ionotropic receptor AMPA type subunit 3, Glutamate receptor, Glutamate receptor 1, Glutamate receptor 2, Glutamate receptor 3, Glutamate receptor 4, Glutamate receptor C, Glutamate receptor ionotrophic AMPA 3, Glutamate receptor ionotrophic AMPA 4, Glutamate receptor ionotropic, Glutamate receptor ionotropic AMPA 1, Glutamate receptor ionotropic AMPA 2, Glutamate receptor ionotropic N methyl D aspartate 1, Glutamate receptor ionotropic N methyl D aspartate 2A, Glutamate receptor ionotropic N methyl D aspartate 3B, Glutamate receptor ionotropic NMDA2B, Glutamate receptor ionotropic, N-methyl-D aspartate, subunit 1, Glutamate receptor ionotropic, NMDA 2C, Glutamate receptor subunit 3, Glutamate receptor subunit epsilon 2, Glutamate receptor, ionotropic, AMPA 3, Glutamate receptor, ionotropic, N-methyl D-aspartate 2D, Glutamate receptor, ionotropic, NMDA2B (epsilon 2), Grin2c, Grin2d, HBGR1, HBGR2, Ionotrophic Glutamate Receptor, Ionotropic Glutamate receptor 4, LKS, MGC133252, MGC142178, MGC142180, MRD6, MRD8, MRX94, N Methly D Aspartate Receptor Channel Subunit Epsilon 3, N methyl D asparate receptor channel subunit epsilon 2, N methyl D aspartate receptor channel subunit zeta 1, N methyl D aspartate receptor channel, subunit epsilon 1, N methyl D aspartate receptor subunit 2A, N methyl D aspartate receptor subunit 2B, N methyl D aspartate receptor subunit 2C, N methyl d aspartate receptor subunit 2D, N-methyl D-aspartate receptor subtype 2A, N-methyl D-aspartate receptor subtype 2B, N-methyl D-aspartate receptor subtype 2C, N-methyl D-aspartate receptor subtype 2D, N-methyl-D-aspartate receptor, N-methyl-D-aspartate receptor subunit 3, N-methyl-D-aspartate receptor subunit NR1, NMD-R1, NMDA 1, NMDA 2D, NMDA NR2B, NMDA receptor 1, NMDA receptor subtype 2A, NMDA receptor subunit 3A, NMDA receptor subunit 3B, NMDAR, NMDAR2C, NMDAR2D, NMDE1_HUMAN, NMDE2_HUMAN, NMDE3_HUMAN, NMDE4_HUMAN, NMDZ1_HUMAN, NR1, NR2A, NR2B, NR2C, NR2D, NR3, OTTHUMP00000041930, OTTHUMP00000160135, OTTHUMP00000160643, OTTHUMP00000165781, OTTHUMP00000174531, OTTHUMP00000224241, OTTHUMP00000224242, OTTHUMP00000224243, dJ1171F9.1, estrogen receptor binding CpG island, glutamate receptor ionotropic NMDA 2D, glutamate receptor ionotropic, NMDA 1, hNR 3, hNR2A
MW 258.05 Da, Purity >99%. Potent NMDA receptor glycine site antagonist. Water soluble form available - see (ab120254).
131123-76-7
> 99%
Solid
258.05 Da
C10H5Cl2NO3
1779
Synthetic
Soluble in 1 eq. NaOH to 50 mM.
5,7-Dichlorokynurenic acid
Potent NMDA receptor glycine site antagonist. Water soluble form available - see (ab120254).
C1=C(C=C(C2=C1NC(=CC2=O)C(=O)O)Cl)Cl
InChI=1S/C10H5Cl2NO3/c11-4-1-5(12)9-6(2-4)13-7(10(15)16)3-8(9)14/h1-3H,(H,13,14)(H,15,16)
BGKFPRIGXAVYNX-UHFFFAOYSA-N
5,7-dichloro-4-oxo-1H-quinoline-2-carboxylic acid
Ambient - Can Ship with Ice
+4°C
+4°C
Store under desiccating conditions, The product can be stored for up to 12 months
This supplementary information is collated from multiple sources and compiled automatically.
The target 'Glutamate Receptor' also known by its subtypes like NMDAR2A NMDAR2B GluN2C NMDAR1 and others serves as an essential component in synaptic transmission in the central nervous system. These receptors are ionotropic meaning they form ion channels and are known for binding to the neurotransmitter glutamate. The GluN2 subunits including GluN2A GluN2B GluN2C and GluN2D contribute to the heteromeric complexes of NMDAR (N-methyl-D-aspartate receptors) which have a role in excitatory neurotransmission. The mass of these receptors varies with their subunits generally within the range of 105-180 kDa. They are expressed widely in the brain with each subtype showing distinct patterns of expression in regions like the hippocampus cortex and cerebellum.
These glutamate receptors play a pivotal role in synaptic plasticity which underpins learning and memory. Within synaptic complexes NMDARs form associations with scaffolding proteins and signal transduction molecules facilitating cellular responses to activity. The AMPA-type glutamate receptors including Glutamate Receptor 1 (GluA1) and Glutamate Receptor 3 (GluA3) collaborate with NMDARs in synaptic transmission by controlling the fast component of excitatory postsynaptic currents. These interactions enable the receptors to modulate synaptic strength and contribute to the maintenance of neural circuits.
These ionotropic glutamate receptors function prominently within the glutamatergic signaling pathway and the calcium signaling pathway. The NMDARs are known to influence calcium influx pivotal for downstream activation of signaling cascades such as CaMKII and MAPK. Related proteins like PSD-95 form complexes with NMDARs mediating cellular responses important for signal transduction. These pathways highlight glutamate receptors' roles in pre- and post-synaptic cellular responses affecting numerous downstream effects that influence neural plasticity and survival.
Disruptions in the function of these glutamate receptors are associated with neurodegenerative diseases and psychiatric disorders. For instance NMDAR malfunction links to Alzheimer's disease due to its involvement in synaptic failure and resultant cognitive deficits. Dysfunctional glutamatergic signaling also connects to schizophrenia where altered NMDAR activity affects neurotransmission and can contribute to symptoms. Proteins like GluA1 also interact in these contexts impacting synaptic plasticity further and potentially exacerbating disease progression through maladaptive synaptic changes.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120023, 5,7-Dichlorokynurenic acid, NMDA receptor glycine site antagonist
ab12416 staining cGMP in SKNSH cells treated with 5,7-Dichlorokynurenic acid (ab120023), by ICC/IF. Decrease in cGMP expression correlates with increased concentration of 5,7-Dichlorokynurenic acid, as described in literature.
The cells were incubated at 37°C for 20 minutes in media containing different concentrations of ab120023 (5,7-Dichlorokynurenic acid) in DMSO. Some samples where then further incubated with 15 µM NMDA (NMDA, excitotoxic amino acid ab120052) for 5 minutes and all samples were fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab12416 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com